Astorg Acquires Thermo Microbiology Unit for $1B+

Thermo Fisher Scientific (TMO) has reached an agreement to divest its microbiology business to private equity firm Astorg for $1.08 billion as the life sciences company optimizes its diagnostics portfolio.

This divestiture represents Thermo Fisher’s strategy to eliminate slower-growing assets while facing challenges from declining post-pandemic demand and concentrate resources on segments with higher margins.

Key Takeaways

Thermo Fisher divesting microbiology unit for $1.08 billion cash
Astorg acquiring business that makes infectious disease testing equipment
Move follows broader industry trend of portfolio optimization

Market reaction & context

This sale emerges as life sciences companies reevaluate their portfolios in the wake of the pandemic boom. Thermo Fisher’s diagnostics division has encountered challenges as COVID-19 testing demand returned to normal levels, creating pressure for the company to refine its asset composition ¹.

The microbiology business produces approximately $300 million in adjusted earnings annually on $1.4 billion in sales, accounting for roughly one-third of Thermo Fisher’s broader specialty diagnostics division. The deal prices the unit at about 3.6 times revenue, consistent with recent diagnostics transactions ².

Strategic rationale

This transaction demonstrates Thermo Fisher’s methodical capital allocation approach as the company aims to divest non-core assets. Earlier in the year, reports emerged that the company was considering the sale of diagnostics unit portions valued at approximately $4 billion ³.

Astorg’s purchase fits with private equity’s increasing appetite for healthcare assets that generate predictable cash flows. The Paris-headquartered firm has previously made investments in medical technology and pharmaceutical services companies throughout Europe ⁴.

Industry consolidation continues

This transaction marks the most recent in a string of diagnostic industry deals as companies streamline their operations. Competitor Becton Dickinson recently announced plans to spin off its life sciences business, including diagnostics segments, demonstrating similar strategic objectives ⁵.

At the same time, Thermo Fisher keeps expanding in faster-growing sectors through acquisitions, recently announcing an $8.9 billion deal to acquire clinical trial data firm Clario from a consortium led by Astorg and Nordic Capital ⁶.

Financial implications

The microbiology sale is structured as $1.08 billion consisting of cash and a $50 million seller note. Thermo Fisher expects to use proceeds to fund growth investments and reduce debt following recent large acquisitions.

The transaction is expected to close in mid-2026, subject to regulatory approvals and customary closing conditions. Upon completion, the divested unit will operate independently under Astorg’s ownership.

Outlook

This divestiture allows Thermo Fisher to concentrate resources on its core laboratory products and biopharma services segments, which present superior growth opportunities. The company has shown consistent implementation of its portfolio optimization strategy in recent years.

For Astorg, this acquisition delivers access to the stable diagnostics market while creating potential for operational enhancements and geographic expansion under private equity ownership.

Not investment advice. For informational purposes only.